Evotec announces Research Agreement with Biogen Idec
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ - Evotec will use its expertise and capabilities in compoundscreening to identify hit compoundsHamburg, Germany / Oxford, UK - Evotec AG (Frankfurt Stock Exchange:EVT; NASDAQ: EVTC), a leading provider in the discovery anddevelopment of novel small molecule drugs, today announced that ithas entered into a research agreement with Biogen Idec (NASDAQ:BIIB), a leading biopharmaceutical company headquartered inCambridge, Mass., USA.Evotec will use its expertise and technologies in protein production,assay development and high throughput screening to identify hitmolecules for Biogen Idec. Under the research agreement Evotec willscreen a target selected by Biogen Idec with the option to addfurther targets as agreed. Evotec will provide Biogen Idec withaccess to its full range of screening technologies and diverselibrary of high quality compounds and will use its expertise inprotein production and assay development to develop new assays forthe target.Dr Mark Ashton, Evotec's EVP, Business Development commented: "Webelieve that the quality of future drug candidates is very muchdependant on the identification of high quality starting points. Tothis end we have established a platform of screening technologiesthat have been proven to identify high-class hit molecules. We arelooking forward to working with Biogen Idec and identifyinginteresting hit compounds for them."Evotec has built a comprehensive platform of hit finding technologiesthat allow it to screen challenging targets and identify new classesof hit compounds that can be progressed towards new treatments forvarious diseases. These proven screening technologies coupled withEvotec's high quality screening library have been shown to unlocknumerous biological targets and identify excellent start points forsubsequent optimization.No financial details are disclosed.For further information, please contact:Dr Werner LanthalerChief Executive OfficerEvotec AG+49.(0)40.56081-242,werner.lanthaler(at)evotec.comKaren SlackDe Facto CommunicationsT : +44 (0) 20 7861 3043E : k.slack(at)defacto.comForward-looking statementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programs and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that the Company maybe unable to reduce its cash burn through recent restructuring andcost containment measures and may not recognize the results of suchmeasures within the expected timeframe; risks that product candidatesmay fail in the clinic or may not be successfully marketed ormanufactured; the risk that we will not achieve the anticipatedbenefits of our collaborations, partnerships and acquisitions in thetimeframes expected, or at all; risks relating to our ability toadvance the development of product candidates currently in thepipeline or in clinical trials; our inability to further identify,develop and achieve commercial success for new products andtechnologies; the risk that competing products may be moresuccessful; our inability to interest potential partners in ourtechnologies and products; our inability to achieve commercialsuccess for our products and technologies; our inability to protectour intellectual property and the cost of enforcing or defending ourintellectual property rights; our failure to comply with regulationsrelating to our products and product candidates, including FDArequirements; the risk that the FDA may interpret the results of ourstudies differently than we have; the risk that clinical trials maynot result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drugcandidates; and risks of new, changing and competitive technologiesand regulations in the U.S. and internationally.The list of risks above is not exhaustive. Our most recent AnnualReport on Form 20-F, filed with the Securities and ExchangeCommission, and other documents filed with, or furnished to theSecurities and Exchange Commission, contain additional factors thatcould impact our businesses and financial performance. We expresslydisclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change inour expectations or any change in events, conditions or circumstanceson which any such statement is based. --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 09.09.2009 - 09:00 Uhr
Sprache: Deutsch
News-ID 5620
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 391 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec announces Research Agreement with Biogen Idec"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
